GLP3 is the research code name for retatrutide, which remains investigational and has no approved product. This page covers that one compound only, with the phase 2 escalation exactly as it was published.
Read this first
Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.
Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.
GLP3 (retatrutide) — phase 2 escalation
Reported quantity
1 mg escalating toward 12 mg weekly in the reported arms
Frequency
Once weekly
Study duration
48 weeks in the published phase 2
The glucagon arm is the distinguishing pharmacology and drives the energy-expenditure endpoints.
Dosage chart
These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.
Retatrutide
Retatrutide Dosage calculations for a 10 mg vial use the same once-weekly amounts studied in human clinical trials. Adding 1 mL of bacteriostatic water produces 10 mg/mL, so each U-100 unit contains 100 mcg.
Reconstitute
Add 1 mL of bacteriostatic water to produce 10 mg/mL.
Research frequency
Once weekly by subcutaneous administration in the cited human trials.
Weekly research range
The cited programs evaluated target amounts through 12 mg weekly.
Easy measuring
1 U-100 unit = 0.01 mL = 100 mcg.
Vial size
The 10 mg label is total nominal vial content, not a weekly amount. Weekly research amounts above 10 mg require enough vials to supply the total nominal mass.
Vial coverage
At the 2 mg research stage, one vial supplies 5 full weekly amounts. At the 12 mg research stage, the 12 mg amount requires 2 separate 10 mg vials by nominal mass. These are mass calculations, not vial storage or discard periods.
The same arithmetic for every vial size GLP3 (retatrutide) is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.
GLP3 (retatrutide) · 3 ml bacteriostatic water
Vial size
Concentration
Per 1 unit
5 mg
1.67 mg/ml
17 mcg
10 mg
3.33 mg/ml
33 mcg
15 mg
5.00 mg/ml
50 mcg
20 mg
6.67 mg/ml
67 mcg
30 mg
10.00 mg/ml
100 mcg
40 mg
13.33 mg/ml
133 mcg
50 mg
16.67 mg/ml
167 mcg
60 mg
20.00 mg/ml
200 mcg
No single reported amount applies to this compound, so only the concentration and the value of one unit are shown. Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.
Reconstitution maths
Research vials are typically 5 mg, 10 mg or 20 mg lyophilised. A 10 mg vial in 1 mL of bacteriostatic water gives 10 mg/mL, so one U-100 unit carries 100 mcg.
Retatrutide is investigational: the evidence base is a single published phase 2 programme, far smaller than the GLP1 or GLP2 datasets.
These are in-vitro research reagents; the trial figures describe a supervised clinical programme.
Research-grade material is not the same molecule quality as trial material; peptide content per vial routinely differs from the labelled mass.
Sources and citations
These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.
[1]
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frías JP, et al. · New England Journal of Medicine · 2023 · PMID 37366315
Adults with obesity were randomized to once-weekly subcutaneous retatrutide at doses up to 12 mg or placebo for 48 weeks in a phase 2 dose-ranging trial.
Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.
Share
Independent publication — we sell nothing. Supplier disclosure
Peptide Intel Hub is an independent educational publication. We are not affiliated with, owned by, or the same company as Regena Peptides and Regena.app (regena-peptides.com / regena.app). We do not sell, supply, ship or take payment for any compound. Because readers regularly ask where compounds discussed in published studies can be sourced for laboratory work, we list Regena Peptides and Regena.app as suppliers we have verified and trust — every batch is released with a lot-matched third-party certificate of analysis (HPLC purity and mass-spectrometry identity). Outbound links are marked nofollow/sponsored and are provided to help readers, not to sell.